The United States has turned to Indian pharmaceutical manufacturers for help in addressing a growing shortage of ifosfamide, a critical chemotherapy drug used to treat several types of cancer. The request from the US Food and Drug Administration (USFDA) underscores India’s growing importance in the global pharmaceutical supply chain and highlights its reputation as the world’s leading supplier of affordable generic medicines.
With supplies of the life-saving cancer drug expected to remain constrained through 2026, Indian drugmakers could play a key role in ensuring uninterrupted treatment for thousands of patients across the United States.
Why is there a shortage of ifosfamide?
The ongoing US cancer drug shortage has been linked to manufacturing disruptions at a contract production facility operated by Baxter International, one of the primary suppliers of ifosfamide.
According to reports, production issues at the facility, combined with supply chain disruptions caused by the conflict in West Asia, have significantly affected the availability of the chemotherapy medicine.
Healthcare providers are concerned because ifosfamide is widely used in the treatment of testicular cancer, soft tissue sarcoma, and certain forms of lymphoma. Since chemotherapy regimens are carefully tailored for individual patients, shortages can force oncologists to modify treatment plans or delay therapy.
Industry estimates suggest that supplies may remain tight throughout 2026, increasing pressure on regulators to identify alternative manufacturing sources.
Why has the USFDA approached India?
India has long been recognised as the “pharmacy of the world”, producing large volumes of affordable generic medicines for global markets.
The country has approximately 10,500 pharmaceutical manufacturing facilities, with more than 350 plants approved by the USFDA. India also accounts for nearly 20% of the world’s generic medicine supply and ranks as the third-largest pharmaceutical producer by volume.
Because many Indian manufacturers already meet stringent international quality standards, they are well positioned to rapidly increase production during medicine shortages.
The USFDA’s outreach to the Indian Drug Manufacturers’ Association (IDMA) reflects confidence in India’s manufacturing capabilities and regulatory compliance.
What is the USFDA approval process for Indian manufacturers?
Indian pharmaceutical companies seeking to supply medicines to the United States must obtain approval from the US Food and Drug Administration (USFDA) before exporting drugs for the American market.
The approval process generally involves:
- Manufacturing facilities undergoing detailed USFDA inspections.
- Compliance with Current Good Manufacturing Practices (cGMP).
- Submission of comprehensive quality, safety and manufacturing data.
- Regular audits and ongoing regulatory monitoring after approval.
- Adherence to strict documentation, quality control and pharmacovigilance standards.
Many Indian pharmaceutical companies already operate USFDA-approved manufacturing plants, enabling them to supply medicines to the United States without requiring entirely new regulatory approvals for existing facilities.
What does this mean for India’s pharmaceutical industry?
The request presents a significant opportunity for Indian pharma exports, particularly for companies specialising in oncology medicines.
Higher exports could increase revenues, strengthen India’s position in global pharmaceutical markets and encourage fresh investments in manufacturing capacity, quality systems and research.
Beyond commercial benefits, the development reinforces India’s reputation as a dependable healthcare partner. In recent years, the country has supplied vaccines, generic medicines and essential drugs worldwide during public health emergencies, further enhancing its global standing.
Will Indian patients face a shortage?
At present, there is no indication that increased exports of ifosfamide will reduce supplies for patients in India.
Pharmaceutical companies typically balance domestic demand with export commitments, while Indian regulators closely monitor the availability of essential medicines.
However, experts continue to stress the importance of safeguarding domestic supplies of life-saving oncology medicines if international demand rises further.
Why uninterrupted access to cancer medicines matters
Cancer remains one of the leading causes of death worldwide, making timely access to chemotherapy drugs essential.
Medicines such as ifosfamide form a critical part of treatment protocols for several cancers. Any disruption in supply can delay treatment, require alternative therapies or complicate patient care.
By seeking assistance from India, the United States aims to minimise treatment disruptions while highlighting the increasingly important role of the Indian pharmaceutical industry in ensuring global medicine security.